icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
JH6w0mDC5ZRKAn9g
Listen
